Specific Metabolic Brain Networks Associated with Parkinsonian and Cerebellar Variants of Multiple System Atrophy
Objective: To identify specific metabolic brain networks for parkinsonian (MSA-P) and cerebellar (MSA-C) variants of MSA. Background: MSA is associated with a disease-related metabolic brain network (MSARP)…Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease
Objective: This study aims to explore pathways of reduced striatal dopamine synthesis in PD that may affect striato-cortical connectivity and implicate in altered glucose metabolism…In vivo evaluation of tau and amyloid pathology in Corticobasal Syndrome
Objective: To assess in vivo, with molecular imaging the brain distribution of tau aggregates ([18F]AV1451 PET) and β-amyloid depositions ([18F]AV45 PET) in patients with Corticobasal…Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease
Objective: To directly compare 18F-DOPA with a highly specific dopamine transporter radioligand 11C-PE2I, for the assessment of motor severity and rate of progression in Parkinson's…PBB3 Imaging in Parkinsonian disorders: evidence for binding to abnormally aggregated proteins in addition to tau proteins
Objective: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 ([11C]methylamino pyridin-3-yl buta-1,3-dienyl benzo[d]thiazol-6-ol) in tauopathies, and in conditions not…Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease
Objective: To describe cortical and subcortical 18F-AV-1451 binding in Parkinson’s disease patients with and without mild cognitive impairment (PD-MCI and PD-nonMCI). Background: The radioligand 18F-AV-1451…Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
Objective: To assess phosphodiesterase 10A (PDE10A) expression in vivo, using [11C]IMA107 PET in patients with PDE10A and adenylate cyclase 5 (ADYC5) mutations. Background: Cyclic adenosine…Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study
Objective: To explore the progression of DA and 5-HT lesions during the course of Parkinson’s disease (PD) and their respective contribution to the pathogenesis of…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 33
- Next Page »